How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/malignant-otitis-externa-due-to-pseudomonas-aeruginosa.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Malignant otitis externa due to Pseudomonas aeruginosa — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Malignant otitis externa due to Pseudomonas aeruginosa (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant otitis externa due to Pseudomonas aeruginosa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Malignant otitis externa due to Pseudomonas aeruginosa
Assistance Publique - Hôpitaux de Paris · 1 drug in Malignant otitis externa due to Pseudomonas aeruginosa
Bayer AG · 1 drug in Malignant otitis externa due to Pseudomonas aeruginosa
Generic (originally Merck) · 1 drug in Malignant otitis externa due to Pseudomonas aeruginosa
Generic (originally Merck/Upjohn) · 1 drug in Malignant otitis externa due to Pseudomonas aeruginosa
Poitiers University Hospital · 1 drug in Malignant otitis externa due to Pseudomonas aeruginosa
University of Zurich · 1 drug in Malignant otitis externa due to Pseudomonas aeruginosa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant otitis externa due to Pseudomonas aeruginosa:

Cite this brief

Drug Landscape (2026). Malignant otitis externa due to Pseudomonas aeruginosa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-otitis-externa-due-to-pseudomonas-aeruginosa. Accessed 2026-06-10.

Malignant otitis externa due to Pseudomonas aeruginosa full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing